Why Product Information Controls Matter
The MHRA has issued a Class 4 Medicines Defect Notification for Milpharm Limited’s Loperamide hydrochloride 2 mg Orodispersible Tablets.
The issue relates to a discrepancy in the approved Patient Information Leaflet. The leaflet incorrectly instructed patients to swallow the tablets whole with water. The correct instruction for this type of tablet is to place it on the tongue and allow it to dissolve, without water. The MHRA also noted that one rare side effect, a burning or prickling sensation of the tongue, was missing from the leaflet.
The notice confirmed that patients did not need to return the medicine and could continue using it as prescribed, following the corrected instructions. Healthcare professionals were asked to note the discrepancy and share the information with patients where appropriate.
For medicines wholesale businesses, this is a clear reminder:
Product information control matters.
What Happened and Why It Matters
This MHRA notification was not about a dramatic product recall from the whole market.
It was about information.
That may sound smaller at first, but in medicines supply, information is not a side issue.
The leaflet, carton, batch details, instructions, warnings and customer communication all help ensure medicines are used, handled and supplied correctly.
If information is wrong, missing or not communicated properly, the business needs a controlled way to respond.
That means knowing:
- What has changed?
- Which batches are affected?
- Who needs to know?
- What should be recorded?
- Does the Responsible Person need visibility?
- Do customers need communication?
- Do SOPs explain what happens next?
These are practical questions, not academic ones.
What This Means for Medicines Wholesale Businesses
Medicines wholesale is often discussed in terms of licences, storage and transport.
Those areas are important, but GDP quality systems also depend on information control.
A business may receive supplier notices, defect notifications, recall alerts, updated leaflets, packaging updates, patient safety communications or customer queries.
If there is no clear process for handling these updates, information can be missed or handled inconsistently.
That can create risk.
A medicines wholesale business should be able to show how it receives, reviews, records and communicates important product information.
This is especially important where the information may affect:
- How a medicine is taken
- How a medicine is stored
- Which batch is affected
- Whether customers need to be informed
- Whether stock needs to be quarantined
- Whether a recall or defect process applies
- Whether the Responsible Person needs to review the issue
The MHRA explains that GDP requires medicines to be obtained from the licensed supply chain and consistently stored, transported and handled under suitable conditions. It also inspects distribution sites for GDP compliance. Product information control supports that wider discipline because the business must understand what it is handling and what instructions or communications apply.
Why Documentation Control Is Not Just Admin
Documentation control is one of the easiest areas for businesses to underestimate.
It can feel like paperwork.
But in a regulated medicines environment, documentation is evidence.
It shows what was received, what was reviewed, who made a decision, what action was taken and whether the business responded properly.
Weak documentation control can create problems such as:
- Supplier notices being missed
- Customer communications being inconsistent
- Outdated information being used
- The Responsible Person not being sighted
- SOPs failing to match real activity
- Records not showing what action was taken
- Staff being unclear on what to do next
These issues can become bigger during inspection, customer review or a quality incident.
Why Responsible Person Visibility Matters
The Responsible Person should have visibility where product information, defect notifications, supplier updates or customer communications may affect GDP quality systems.
That does not mean the Responsible Person personally handles every email or leaflet.
But the system should make sure important information reaches the right person at the right time.
A good process should answer:
- Who receives MHRA and supplier notifications?
- Who decides whether action is needed?
- Who informs the Responsible Person?
- Who communicates with customers where required?
- Who records the outcome?
- Who checks that future batches or documents have been corrected?
- If those answers are unclear, the quality system may need strengthening.
What Businesses Should Check Now
If your business is involved in medicines wholesale, WDA(H) readiness, specialist distribution or ongoing GDP compliance, this is a good time to review your product information controls.
Start with these checks:
- Review who receives MHRA alerts and supplier notices.
- Check how product information updates are logged.
- Review whether affected batches can be identified quickly.
- Check whether customer communication routes are clear.
- Review whether the Responsible Person has visibility of relevant issues.
- Check whether SOPs explain what happens when a leaflet, carton or product notice changes.
- Review whether staff know what to do with defect notifications.
- Check whether records show what was reviewed and what action was taken.
- Review whether documentation control works in real life, not just on paper.
- Check whether repeated issues are considered through deviation or CAPA processes.
These checks are not about creating unnecessary administration.
They are about making sure important information is controlled, visible and acted on properly.
How Stag Global Helps
Stag Global does not supply medicines or products.
We support businesses with compliance-led review and readiness support.
This may include:
- GDP quality system review
- Responsible Person / GDP quality support
- SOP and documentation control review
- Product information control review
- Supplier and customer communication review
- Defect notification process review
- Compliance route reviews
- WDA(H) application readiness
- Ongoing compliance support
- Inspection readiness support
Our role is to help businesses understand whether their systems are clear, practical and strong enough before small gaps become bigger risks.
We help clients move forward with clarity, control and confidence.
Final Thought
The latest MHRA defect notification is a reminder that medicines compliance is not only about the physical product.
It is also about the information that travels with the product.
For medicines wholesale businesses, the key question is simple:
Can you receive, review, record and communicate important product information in a controlled and defensible way?
If the answer is unclear, now is the time to review your GDP quality system.
Need clarity on your product information controls, documentation process or Responsible Person oversight?
Book a confidential consultation with Stag Global to review your GDP quality system before small gaps become bigger compliance risks.
